1-5 of 5
K Bradstock
Close
Sort by
Journal Articles

BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.

Susan Branford, Z. Rudzki, A. Grigg, J. F. Seymour, K. Taylor, P. Browett, A. Schwarer, K. Bradstock, C. Arthur, S. Durrant, D. Ma, D. Joske, K. Lynch, T. Hughes
Journal: Blood
Blood (2004) 104 (11): 274.
https://doi.org/10.1182/blood.V104.11.274.274
Published: 2004
Journal Articles

Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia

J Brisco, E Hughes, SH Neoh, PJ Sykes, K Bradstock, A Enno, J Szer, K McCaul, AA Morley
Journal: Blood
Blood (1996) 87 (12): 5251–5256.
https://doi.org/10.1182/blood.V87.12.5251.bloodjournal87125251
Published: 1996
Journal Articles

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]

JF Bishop, JP Matthews, GA Young, J Szer, A Gillett, D Joshua, K Bradstock, A Enno, MM Wolf, R Fox
Journal: Blood
Blood (1996) 87 (5): 1710–1717.
https://doi.org/10.1182/blood.V87.5.1710.1710
Published: 1996
Journal Articles

Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group

K Bradstock, J Matthews, E Benson, F Page, J Bishop
Journal: Blood
Blood (1994) 84 (4): 1220–1225.
https://doi.org/10.1182/blood.V84.4.1220.1220
Published: 1994
Journal Articles

Analysis of the mechanism of adhesion of precursor-B acute lymphoblastic leukemia cells to bone marrow fibroblasts

K Bradstock, V Makrynikola, A Bianchi, K Byth
Journal: Blood
Blood (1993) 82 (11): 3437–3444.
https://doi.org/10.1182/blood.V82.11.3437.3437
Published: 1993